KPTI, US48576U2050

Karyopharm Therapeutics stock sits 95.48 percent below target

Published on 10/24/2026 at 21:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Karyopharm's next report is estimated for November 2, 2026 before market opens. Karyopharm Therapeutics stock costs EUR 0.46 on October 24, 2026.

Analyst target and reporting date

MarketBeat listed a USD 11.50 consensus target from seven analysts on October 23, 2026, 95.48 percent above the Nasdaq close of USD 0.52.
MarketBeat estimated Karyopharm's third-quarter 2026 results for November 2, 2026, before market open.
Karyopharm Therapeutics stock costs EUR 0.46 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Second-quarter 2026 revenue was USD 33.43 million, versus a USD 32.19 million consensus estimate.

KPTI, US48576U2050, Illustration mit AI erstellt.

Karyopharm Therapeutics (US48576U2050) stock sits 95.48 percent below the USD 11.50 consensus target listed for seven analysts by MarketBeat on October 23, 2026. The same source estimated the next quarterly report for November 2, 2026, before market open. At Lang & Schwarz, the stock was trading at EUR 0.46 on October 24, 2026 at 1:04 p.m. CEST.

Consensus leaves a wide valuation gap

MarketBeat's USD 11.50 average target is based on seven analysts, while the Nasdaq close was USD 0.52 on October 23, 2026. That places the target 2,111.54 percent above the closing price, or the closing price 95.48 percent below the target. The figures describe a wide spread in expectations rather than a confirmed company forecast.

Revenue beat expectations in the second quarter

MarketBeat said Karyopharm reported USD 33.43 million in second-quarter 2026 revenue, above the USD 32.19 million consensus estimate. The company also reported adjusted earnings per share of minus USD 2.32, missing the consensus estimate of minus USD 1.37, on August 13, 2026.

November 2 carries the next date

The upcoming report is expected to cover the third quarter of 2026. Karyopharm Therapeutics describes itself as a commercial-stage oncology company focused on selective inhibitors of nuclear export, led by XPOVIO, or selinexor. Its investor-relations profile identifies the company as Nasdaq-listed under KPTI.

EUR 0.46 at Lang & Schwarz

The euro quotation gives German-market readers a current Saturday indication at EUR 0.46. The Nasdaq close was USD 0.52 on October 23, 2026, while the Nasdaq 52-week range stood at USD 0.31 to USD 10.99 and market capitalization at USD 11.7 million, according to MarketBeat's October 23, 2026 figures.

The further course of trading is shown by the continuously updated real-time quote of Karyopharm Therapeutics stock.